Compare PPSI & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | VERU |
|---|---|---|
| Founded | 2008 | 1971 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 40.9M |
| IPO Year | 2008 | 1996 |
| Metric | PPSI | VERU |
|---|---|---|
| Price | $3.99 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 275.4K | 56.4K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,627,000.00 | $16,296,958.00 |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $22.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.75 | N/A |
| 52 Week Low | $2.35 | $0.36 |
| 52 Week High | $5.70 | $4.59 |
| Indicator | PPSI | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 36.49 |
| Support Level | $3.94 | $0.36 |
| Resistance Level | $4.49 | $2.67 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 48.18 | 18.18 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets. The Company launched two new product platforms namely, PRYMUS, a new, mobile on-site power system concentrating on customers with requirements of 1-10 megawatts of mobile power and PowerCore, a residential and small commercial based primary generator system integrating a DC fast charger into one solution.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.